- Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
-
Bertoletti A, Tan AT
- KMID: 2563478
- Clin Mol Hepatol.
- 2025 Jan;31(1):e113-e116.
- doi: 10.3350/cmh.2024.0867
-
- CITED
-
- Close
- SHARE
-
- Close
- Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
-
Bertoletti A, Tan AT
- KMID: 2560082
- Clin Mol Hepatol.
- 2024 Oct;30(4):728-734.
- doi: 10.3350/cmh.2024.0469
-
- CITED
-
- Close
- SHARE
-
- Close
- Immunotherapy for Chronic Hepatitis B Virus Infection
-
Bertoletti A, Le Bert N
- KMID: 2424077
- Gut Liver.
- 2018 Sep;12(5):497-507.
- doi: 10.5009/gnl17233
While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal. Although current direct... -
- CITED
-
- Close
- SHARE
-
- Close
